Método de expansión de linfocitos T y usos

• Main Author: GRÖNLUND, Hans
• Format: Patent
• Language: Spanish
• Published: 11.10.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

O una secuencia de aminoácidos mutada o no mutada que se sabe o se sospecha que se expresa en una célula cancerosa del sujeto; b) proporcionar una célula presentadora de antígeno viable; c) poner en contacto la partícula con la célula presentadora de antígeno in vitro en condiciones que permitan la fagocitosis de la partícula por la célula presentadora de antígeno; d) proporcionar una muestra de células T que comprende células T viables del sujeto; e) poner en contacto la muestra de células T con la célula presentadora de antígeno en contacto con la partícula in vitro en condiciones que permitan la activación específica de células T antitumorales en respuesta al antígeno presentado por la célula presentadora de antígeno. La invención también proporciona construcciones neoantigénicas tumorales como se define en la especificación. (Traducción automática con Google Translate, sin valor legal) The invention provides a method for the expansion of anti-tumor T-cells, comprising the steps of:a) providing a phagocytosable particle, having one or more tumor neoantigenic constructs tightly associated thereto, wherein the tumor neoantigenic construct comprises an amino-acid sequence comprising at least one mutated amino acid known or suspected to be associated with a cancer in a subject, or a mutated or non-mutated amino-acid sequence known or suspected to be expressed in a cancer cell in the subject;b) providing a viable antigen-presenting cell;c) contacting the particle with the antigen-presenting cell in vitro under conditions allowing phagocytosis of the particle by the antigen-presenting cell;d) providing a T-cell sample comprising viable T-cells from the subject;e) contacting the T-cell sample with the antigen-presenting cell contacted with the particle in vitro under conditions allowing specific activation of anti-tumor T-cells in response to antigen presented by the antigen-presenting cell.The invention also provides tumor neoantigenic constructs as defined in the specification.